Renascience

Renascience Net Tangible Assets

The Net Tangible Assets of Renascience (4889.T) as of Nov 19, 2026 is 3.32 B JPY. In the previous year, Net Tangible Assets was 1.72 B JPY — a change of 93.16% (higher).

Net Tangible Assets

3.32 BJPY

YoY

93.16%

Last updated:

Net Tangible Assets of Renascience is 2026 3.32 B JPY. Net Tangible Assets of Renascience was 2025 1.72 B JPY. It decreases by 93.16% higher compared to the previous year.

The Renascience Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2020
606.30 M JPY
Jan 1, 2021
548.26 M JPY
Jan 1, 2022
2.20 B JPY
Jan 1, 2023
1.86 B JPY
Jan 1, 2024
1.61 B JPY
Jan 1, 2025
1.72 B JPY
Jan 1, 2026
3.32 B JPY
The Renascience Net Tangible Assets history
YEARNet Tangible AssetsYoY
3.32 BJPY+93.16%
1.72 BJPY+7.06%
1.61 BJPY-13.84%
1.86 BJPY-15.27%
2.20 BJPY+301.43%
548.26 MJPY-9.57%
606.30 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Net Tangible Assets of Renascience is 3.32 B JPY in 2026.

Net Tangible Assets of Renascience changed from 1.72 B JPY to 3.32 B JPY, representing a 93.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Renascience since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Renascience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Renascience

All Key Metrics — Renascience